Introduction
Nuclear factor kB-inducing kinase (NIK) is a serine/ threonine protein kinase belonging to the MAP kinase kinase kinase family, which also includes MEKK1-4, ASK1, and Raf, among others (Malinin et al., 1997) . NIK was first identified as a TRAF2-interacting protein by yeast two-hybrid screening and was shown to be involved in the TNF-R1-induced NF-kB activation pathway (Malinin et al., 1997 ) (TNF, tumor necrosis factor; nuclear factor kappaB, NF-kB). Subsequently, it has been suggested that NIK interacts with various TRAFs and can activate IKK, a kinase complex that is critically involved in NF-kB activation triggered by divergent stimuli (Lin et al., 1998a, b) . However, gene knockout experiments indicate that NIK is essential for lymphotoxin-b-but not TNF-R-induced NF-kB activation (Matsushima et al., 2001; Yin et al., 2001) . Furthermore, it is suggested that NIK functions at a nuclear rather than a cytoplasmic step in the lymphotoxin-b-induced NF-kB activation pathway (Yin et al., 2001) . Since a kinase inactive mutant of NIK can block NF-kB activation by various stimuli, such as TNF, IL1, and LPS, this suggests that NIK may be involved in a broad range of NF-kB activation pathways.
Previously, it has been shown that epidermal growth factor (EGF) can activate NF-kB through undefined pathways (Obata et al., 1996; Sun and Carpenter, 1998; Biswas et al., 2000; Habib et al., 2001) . EGF family members interact with receptors belonging to the EGF receptor family, including epidermal growth factor receptor (EGFR), epidermal growth factor receptor family protein (ErbB)2, ErbB3, and ErbB4 (Pawson, 1995) . The cytoplasmic domains of the EGF receptor family members, except for ErbB2, have intrinsic tyrosine kinase activity. Ligand stimulation leads to homo-or heterodimerization of the EGF receptor family members and their autophosphorylation. This process creates docking sites for downstream signaling molecules that contain the SH2 domain (Pawson, 1995) . Interaction of these signaling molecules with the receptors initiates intracellular signaling cascades that lead to activation of a number of transcription factors such as AP-1 and STATS (Hill and Treisman, 1995) . Previous studies also suggest that EGF can activate NFkB in several types of cells, including smooth muscle, A431, fibroblasts, and EGF receptor-overexpressing breast cancer cells (Obata et al., 1996; Sun and Carpenter, 1998; Biswas et al., 2000; Habib et al., 2001) .
The growth factor receptor bound (Grb)7 family members are some of the adapter molecules that interact with activated receptor tyrosine kinases, including the EGF receptor family members. The Grb7 family consists of Grb7, Grb10, and Grb14, which do not have intrinsic enzymatic activity and signal through their interaction with downstream proteins (Daly, 1998; Han et al., 2001) . Unlike Grb2, which contains an SH2 domain flanked by two SH3 domains, the Grb7 family members contain an N-terminal proline-rich (PR) region, a central GM region that is homologous with the C. elegans protein Mig10, and a C-terminal SH2 domain (Daly, 1998; Han et al., 2001) . The SH2 domain of the Grb7 family is responsible for interaction with the majority of identified Grb7-interacting proteins, such as the EGF receptor family members, Shc, Raf, Tek/Tie2, and FAK, among others (Han et al., 2001) . It has been shown that the PR domain of Grb7 family members interacts with c-Abl and Tankyrase (Frantz et al., 1997; Han et al., 2001; Lyons et al., 2001) . Proteins that interact with the large central GM domain of the Grb7 family members are not known.
In addition to their roles in EGF receptor signaling, the Grb7 family members play divergent roles in various signaling pathways and pathophysiological processes. Grb7 is overexpressed in some human primary cancers and tumor cell lines, suggesting a possible role in tumorigenesis (Stein et al., 1994) . Various studies have also suggested a role for Grb7 in the regulation of cell migration (Tanaka et al., 1998; Han and Guan, 1999; Han et al., 2000; Lee et al., 2000; Vaysssiere et al., 2000) . Grb10 has been found to be associated with mitochondria, where it interacts with Raf1 and is likely to be involved in the regulation of apoptosis (Nantel et al., 1998 (Nantel et al., , 1999 . It was also reported that Grb10 is recruited to the c-Kit receptor in the course of SCF-mediated activation of c-Kit and forms a complex with Akt (Jahn et al., 2002) . Grb14 was recently shown to be a specific inhibitor of insulin receptor catalytic activity (Berezia et al., 2002) .
To unambiguously identify the signaling pathways that NIK participates in, we searched NIK-associated proteins by screening antibody arrays. This effort identified ErbB4 and Grb7 as two proteins that are associated with NIK. Our findings suggest that NIK is a component of the EGF/heregulin receptor signaling complexes and involved in NF-kB activation by these receptors.
Results

Identification of NIK-associated proteins by screening of antibody arrays
To search for potential NIK-associated proteins, we used the Signal Transduction Antibody ArrayTM system (Hypromatrix, Inc.). Each Antibody ArrayTM membrane contains 400 antibodies against well-studied proteins. The antibodies are immobilized on a nitrocellulose membrane, each at a predetermined position, and they retain their capabilities of recognizing and capturing antigens as well as antigen-associated proteins. We transfected 293 cells with an expression plasmid for Flag-NIK and the cell lysate was used to incubate with the antibody array membrane. Using anti-Flag antibody, we detected that 21 antibodies could recruit Flag-NIK, probably directly or indirectly through their antigens. These include antibodies against NBK, Mad-1, p38, CD3-e, eNOS, HSP-70, ANT, DAXX, SODD, thyroid receptor a1, Sp1, ErbB4, TNF-R1, B7-1, DMBT1, GATA-1, IRF2, TRADD, BOK, caspase-2, and Grb7. Results for part of the membrane are shown in Figure 1 . Previously, it was shown that Grb7 is associated with EGF receptor family members, including EGFR, ErbB2, ErbB3, and ErbB4 (Margolis et al., 1992; Stein et al., 1994; Janes et al., 1997; Daly, 1998; Fiddes et al., 1998; Han et al., 2001) . Thus, recruitment of NIK to two independent antibodies against ErbB4 and Grb7, respectively, suggests a high possibility that NIK is a true component of the ErbB4/Grb7 signaling complex.
NIK interacts with Grb7, Grb10, and Grb14, but not Grb2
To determine whether NIK interacts with Grb7, we transfected 293 cells with expression plasmids for HAtagged NIK and Flag-tagged Grb7 and performed immunoprecipitation experiments. These experiments suggest that NIK interacts with Grb7 in 293 cells ( Figure 2 ). The Grb7 adapter family contains three members, including Grb7, Grb10, and Grb14 (Daly, 1998; Han et al., 2001) . Coimmunoprecipitation experiments indicate that NIK also interacts with Grb10 and Grb14 ( Figure 2 ). These interactions are specific because Grb2, an adapter protein not belonging to the Grb7 family, does not interact with NIK under the same condition ( Figure 2 ).
Domain mapping of interaction between Grb7 and NIK
It has been shown that the SH2 domain of Grb7 family members is responsible for interaction with most 
NIK is a component of the EGF/heregulin D Chen et al identified binding partners (Daly, 1998; Han et al., 2001) . To determine which domain of Grb7 interacts with NIK, we constructed a series of HA epitope-tagged deletion mutants of Grb7, including Grb7(1-102) (the PR domain), Grb7(1-418) (the PR and GM domains), Grb7(103-533) (the GM and SH2 domains), and Grb7(103-418) (the GM domain). We cotransfected these deletion mutants with Flag-tagged NIK into 293 cells and performed coimmunoprecipitation experiments. These experiments suggest that the central GM domain of Grb7, aa103-418, is sufficient for its interaction with NIK ( Figure 3 ).
NIK is recruited to EGF/heregulin receptor signaling complexes
To determine whether NIK is recruited to EGF/ heregulin receptor signaling complexes, we transfected 293 cells with expression plasmids for HA-tagged Grb7 and NIK, together with Flag-tagged ErbBs, and performed coimmunoprecipitation experiments. The results suggest that Grb7 and NIK can be simultaneously recruited to all EGF/heregulin receptors, including EGFR, ErbB2, ErbB3, and ErbB4 ( Figure 4a ). We also found that EGFR/ErbB2 could form a complex with Grb7, Grb10, Grb14, and NIK, respectively ( Figure 4b ).
We next determined whether NIK is associated with Grb7 and the EGF receptors in untransfected cells. Previously, it was shown that Grb7 is coamplified, overexpressed, and in a tight complex with ErbB2 (Stein et al., 1994; Akiyama et al., 1997; Tanaka et al., 1997) . Therefore, we have used a breast cancer cell line, MCF7, for endogenous coimmunoprecipitation experiments. The results suggest that NIK is constitutively associated with Grb7 and the EGFR/ErbB2 complex (Figure 4b ). It is possible that the EGFR/ErbB2 complex is constitutive active in MCF7 cells and thus results in a constitutive recruitment of NIK to the complex. 
Grb7 collaborates with NIK to activate NF-kB
It has been shown that NIK is involved in NF-kB activation (Malinin et al., 1997; Lin et al., 1998a, b; Yin et al., 2001) . To determine whether Grb7 has a similar function, we performed NF-kB luciferase reporter gene assays. These experiments indicated that overexpression of Grb7 could weakly activate NF-kB in a dose-dependent manner (Figure 5a ). In addition, Grb7 could collaborate with NIK to activate NF-kB (Figure 5a ). To exclude the possibility that Grb7 affects NIK expression but not NIK signaling, we examined NIK levels in all transfections by Western blot analysis. As shown in Figure 5a , NIK levels were not significantly changed with the increased expression of Grb7. ) were transfected with expression plasmids for Flagtagged EGFR and ErbB2 (each 10 mg), together with expression plasmids for HA-tagged NIK and Flag-tagged Grb7, Grb10, or Grb14 (each 10 mg). Coimmunoprecipitation was performed with anti-EGFR and anti-ErbB2 antibodies (aEGFR þ aErbB2) or control IgG (C), and Western blot was performed with anti-HA and anti-Flag antibody mixture. (c) NIK is associated with Grb7 and EGF receptors in untransfected cells. MCF7 cells (B2 Â 10 7 ) were lysed and the lysate was immunoprecipitated with a mixture of rabbit anti-EGFR (1 mg) þ anti-ErbB2 (1 mg) antibodies, rabbit anti-Grb7 antibody (2 mg), or rabbit control IgG (2 mg). Western blot analysis was performed with rabbit anti-NIK antibody We also determined the effects of different Grb7 domains on NIK-induced NF-kB activation. These experiments suggest that the N-terminal PR domain (aa1-102) can inhibit NIK-induced NF-kB activation, while the central GM domain is sufficient for collaboration with NIK to activate NF-kB (Figure 5b) . Moreover, the SH2 domain of Grb7 can enhance its collaborative ability in NIK-induced NF-kB activation (Figure 5b ).
NIK is involved in NF-kB activation mediated by EGF/ heregulin receptors
To determine the role of Grb7 in the NF-kB activation pathways mediated by ErbBs, we performed NF-kB luciferase reporter gene assays. The results indicated that overexpression of ErbB2/ErbB4 could activate NFkB and this was enhanced by EGF stimulation (Figure 6a ). In these assays, NIK could collaborate with ErbB2/ErbB4 and Grb7 to activate NF-kB. On the other hand, a kinase inactive mutant of NIK, but not that of MEKK3, inhibited ErbB2/ErbB4-mediated NFkB activation (Figure 6a ). To determine whether NIK is involved in EGF/ heregulin receptor-induced NF-kB activation under physiological conditions, we examined whether EGF/ heregulin receptors can activate NF-kB in NIK-deficient embryonic fibroblasts by reporter gene assays. As shown in Figure 6b , c, we found that EGF/heregulin receptors could activate NF-kB in wild-type, but not NIKdeficient cells. Taken together, these data suggest that NIK is a component of EGF/heregulin receptormediated NF-kB activation pathways.
Discussion
NIK is a serine/threonine protein kinase that has been implicated in NF-kB activation pathways. In this study, we found that NIK interacts with Grb7 family members and is a component of the EGF/heregulin receptormediated NF-kB activation pathways. Our studies support previous reports that EGF/heregulin can activate the transcriptional factor NF-kB (Obata et al., 1996; Sun and Carpenter, 1998; Biswas et al., 2000; Habib et al., 2001 ) and further provide a mechanistic explanation for this observation.
Grb7 was initially identified as an EGF receptor binding protein (Margolis et al., 1992) ; thereafter many other binding partners have been reported for Grb7. These include HER2/Shc, SHPTP2, PDGFR, ErbB2, ErbB3, ErbB4, c-Kit, FAK, Tek/Tie2, c-Kit/SCFR, Rnd1, IR, and caveolin (Han et al., 2001) . Most of these binding partners are upstream regulators of Grb7 family proteins. Little is known about potential downstream effectors of the Grb7 family proteins. Previous studies have shown that the PR domain of Grb10 interacts with c-Abl in vitro (Frantz et al., 1997) . It has also been suggested that the PR domain of Grb14 interacts with Tankyrase in the mammalian overexpression system and this interaction is involved in vesicle trafficking (Lyons et al., 2001) . However, it is unknown whether these proteins are associated with the Grb7 family members in untransfected cells.
In this study, we identified NIK as a protein interacting with the GM domain of Grb7. NIK also interacts with Grb10 and Grb14, two other members of the Grb7 family. As far as we know, NIK is the first protein that has been shown to interact with the large central GM domain of the Grb7 family members. Endogenous coimmunoprecipitation experiments have suggested that NIK is associated with Grb7 and is a component of the EGF receptor signaling complex. A kinase inactive mutant of NIK, but not that of MEKK3, inhibits Grb7 and ErbB2/ErbB4-mediated NF-kB activation. Moreover, experiments with NIK-deficient embryonic fibroblasts indicate that NIK is required for EGF/heregulin receptor-mediated NF-kB activation. Therefore, we propose that NIK is a downstream effecter of EGF/heregulin receptor-mediated NF-kB activation pathways.
Previously, it has been shown that the Grb7 family members are phosphorylated on serine and threonine residues (Stein et al., 1994; Ooi et al., 1995; Daly et al., 1996; Dong et al., 1997; Reilly et al., 2000) . The phosphorylation is either constitutive or can be induced by stimulation with growth factors, such as EGF, heregulin, and PDGF. Since NIK is a serine/threonine protein kinase, it would be interesting to examine whether NIK is responsible for the serine/threonine phosphorylation of the Grb7 family members. It is also possible that NIK functions as a kinase for other downstream signaling proteins, for example, c-Abl and Tankyrase, two proteins that are associated with the PR domain of the Grb7 family members.
Grb7 has been shown to be amplified and overexpressed in concert with ErbB2 in several breast cancer cell lines and other cancer cell types (Margolis et al., 1992; Akiyama et al., 1997; Tanaka et al., 1997) . It has also been shown recently that EGF-induced NF-kB activation was a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells (Biswas et al., 2000) . In addition, human tumor cell lines resistant to TNF express high levels of EGFR, ErbB2, or ErbB3 (Hoffmann et al., 1998) . Since NF-kB activation can prevent cells from apoptosis induced by divergent stimuli (Van Antwerp et al., 1996; Beg and Baltimore, 1996; Liu et al., 1996; Wang et al., 1998) , it is possible that NF-kB activation is involved in cell proliferation and malignancy triggered by overexpression of EGF receptor family members. The identification of NIK as a component of EGF/heregulin receptormediated NF-kB activation pathways may therefore provide a molecular target for drug development against cancers caused by overexpression of EGF/heregulin receptor family members.
Materials and methods
Reagents
Recombinant EGF and heregulin (R&D Systems), monoclonal antibodies against FLAG and the HA (Sigma) epitopes, rabbit polyclonal antibodies against EGFR, ErbB2, Grb7 and NIK (Santa Cruz Biotechnology), and 293 cells (ATCC) were purchased from the indicated resources. Wild-type and NIKdeficient mouse embryonic fibroblasts (Dr Robert Schreiber, Washington University at St Louis), and MCF7 cells (Dr Gary Johnson, University of Colorado Health Sciences Center) were provided by the indicated investigators.
Constructs
NF-kB luciferase reporter construct (Dr Gary Johnson, University of Colorado Health Sciences Center), mammalian expression plasmids for Flag-NIK (Dr David Goeddel, Tularik Inc.), EGFR, ErbB2-4 (Dr Gibbes Johnson, Center for Biologics Evaluation and Research) were provided by the indicated investigators. Mammalian expression plasmids for HA-NIK, HA-or FLAG-tagged Grb2, Grb10, Grb14, Grb7 and its deletion mutants were constructed by PCR amplifica-tion of the corresponding cDNA fragments and subsequently cloning into a CMV promoter-based vector containing a 5 0 or 3 0 HA or FLAG tag.
Antibody array screening
The antibody arrays that contain 400 antibodies were purchased from Hypromatrix, Inc. To screen for NIKassociated proteins, 293 cells (5 Â 10 6 ) were transfected with 10 mg of expression plasmid for Flag-NIK. At 24 h after transfection, cells were lysed in 1 ml of Triton Extraction Solution (15 mm Tris, pH 7.5, 120 mm NaCl, 1% Triton, 25 mm KCl, 2 mm EGTA, 2 mm EDTA, 0.1 mm DTT, 0.5% Triton X-100, 10 mg/ml leupeptin, 0.5 mm phenylmethylsulfonyl fluoride). The cell lysate was collected and applied to preblocked Antibody ArrayTM membranes for 2 h. The membranes were then washed with TBS-T buffer (150 mm NaCl, 25 mm Tris, 0.05% Tween-20, pH 7.5) and incubated with HRP-conjugated anti-Flag antibody for 2 h at room temperature. The membranes were washed again and the signals were detected by ECL.
Cell transfection and reporter gene assays 293 cells (1 Â 10 5 ) were seeded in 12-well dishes and transfected the following day by the standard calcium phosphate precipitation (Sambrook et al., 1989) . Mouse embryonic fibroblasts (1 Â 10 5 ) were seeded in 12-well dishes and transfected the following day with Lipofectamine 2000 reagent (Invitrogen) by following procedures suggested by the manufacturer. Within the same experiment, each transfection was performed in triplicate and, where necessary, empty control plasmid was added to ensure that each transfection receives the same amount of total DNA. To normalize for transfection efficiency, 0.1 mg of pRL-TK Renilla luciferase or RSV-b-galactosidase reporter plasmid was added to each transfection. Luciferase and b-galactosidase assays were performed as previously described (Chen et al., 2002) . Luciferase activities were normalized on the basis of Renilla luciferase or b-galactosidase expression levels.
Coimmunoprecipitation and Western blot analysis
For transient transfection and coimmunoprecipitation experiments, transfected 293 cells from each 100-mm dish were lysed in 1 ml of lysis buffer (15 mm Tris, 120 mm NaCl, 1% Triton, 25 mm KCl, 2 mm EGTA, 2 mm EDTA, 0.1 mm DTT, 0.5% Triton X-100, 10 mg/ml leupeptin, 0.5 mm phenylmethylsulfonyl fluoride, pH 7.5). For each immunoprecipitation, a 0.4-ml aliquot of lysate was incubated with 0.5 mg of the indicated monoclonal antibody or control mouse IgG and 25 ml of 1 : 1 slurry of GammaBind A Plus-Sepharose (Amersham Pharmacia) for at least 2 h. The sepharose beads were washed three times with 1 ml of lysis buffer. The precipitates were fractionated on SDS-PAGE and subsequent Western blot analysis was performed as described (Chen et al., 2002) .
For endogenous coimmunoprecipitation, MCF cells (B6 Â 10 7 ) were lysed in 3 ml of lysis buffer. A 1 ml aliquot of lysate was incubated with a mixture of rabbit anti-EGFR (1 mg) and anti-ErbB2 (1 mg) antibodies, a rabbit anti-Grb7 antibody (2 mg), or control rabbit IgG (2 mg). The subsequent immunoprecipitation and Western blot (with a rabbit anti-NIK antibody) experiments were performed as described above.
All immunoprecipitation experiments were performed at least two times and similar results were obtained.
Abbreviations NIK, nuclear factor kB-inducing kinase; Grb, growth factor receptor bound; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor family protein; EGF, epidermal growth factor; TRADD, tumor necrosis factor associated death domain protein; RIP, receptor interacting protein; TNF, tumor necrosis factor; NF-kB, nuclear factor kappaB; STAT, signal transducers and activators of transcription.
